BioLife Solutions (NASDAQ:BLFS) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Key Points

• BioLife Solutions (BLFS) crossed below its 200‑day moving average — the stock last traded at $21.72 versus the 200‑day MA of $23.73 and traded as low as $21.29 (roughly a 4.7% decline on the day).
• Analyst and ownership signals are mixed: MarketBeat shows a consensus rating of "Moderate Buy" with a $32 average price target, while insiders have sold ~99,641 shares in the past 90 days and institutional investors own about 93.24% of the stock.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $23.73 and traded as low as $21.29. BioLife Solutions shares last traded at $21.72, with a volume of 483,605 shares.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. UBS Group reaffirmed a "buy" rating on shares of BioLife Solutions in a report on Monday, December 29th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioLife Solutions in a report on Monday. Wall Street Zen raised shares of BioLife Solutions from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. Northland Securities set a $34.00 price objective on shares of BioLife Solutions in a report on Monday, January 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price objective on shares of BioLife Solutions in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioLife Solutions has an average rating of "Moderate Buy" and a consensus price target of $32.00.

BioLife Solutions Trading Down 4.7%

The company's fifty day simple moving average is $20.57 and its 200 day simple moving average is $23.73. The stock has a market capitalization of $1.05 billion, a P/E ratio of -197.44 and a beta of 2.00.

Insider Buying and Selling at BioLife Solutions

In other news, insider Karen A. Foster sold 96,923 shares of the firm's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the sale, the insider owned 113,742 shares in the company, valued at approximately $2,291,901.30. This trade represents a 46.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 99,641 shares of company stock worth $2,009,000. Company insiders own 2.20% of the company's stock.

Institutional Trading of BioLife Solutions

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Louisiana State Employees Retirement System purchased a new stake in shares of BioLife Solutions during the 1st quarter valued at $330,000. SG Americas Securities LLC raised its position in shares of BioLife Solutions by 25.5% during the 1st quarter. SG Americas Securities LLC now owns 34,036 shares of the medical equipment provider's stock valued at $649,000 after buying an additional 6,908 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of BioLife Solutions by 27.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider's stock valued at $125,273,000 after buying an additional 1,113,972 shares in the last quarter. Invesco Ltd. raised its position in shares of BioLife Solutions by 9.2% during the 4th quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider's stock valued at $95,080,000 after buying an additional 332,747 shares in the last quarter. Finally, XTX Topco Ltd raised its position in shares of BioLife Solutions by 280.4% during the 4th quarter. XTX Topco Ltd now owns 36,262 shares of the medical equipment provider's stock valued at $877,000 after buying an additional 26,729 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions NASDAQ: BLFS specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.